142 related articles for article (PubMed ID: 32668063)
21. Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.
Cohen JB; Kahl BS
Hematol Oncol Clin North Am; 2020 Aug; 34(4):663-672. PubMed ID: 32586572
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
[No Abstract] [Full Text] [Related]
23. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
Prettyjohns M; Hoskin P; McNamara C; Linch D;
Br J Haematol; 2018 Jan; 180(1):52-59. PubMed ID: 29076139
[TBL] [Abstract][Full Text] [Related]
24. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
[TBL] [Abstract][Full Text] [Related]
25. Impact of age on genetics and treatment efficacy in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Bararia D; Häbe S; Hellmuth JC; Kridel R; Gascoyne R; Schmidt C; Zöllner AK; Buske C; Dreyling M; Unterhalt M; Hiddemann W; Hoster E; Weigert O
Haematologica; 2018 Aug; 103(8):e364-e367. PubMed ID: 29545350
[No Abstract] [Full Text] [Related]
26. Biosimilars: when a negative study can be positive.
Link BK
Lancet Haematol; 2018 Nov; 5(11):e500-e501. PubMed ID: 30389032
[No Abstract] [Full Text] [Related]
27. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
Ochi Y; Hiramoto N; Ono Y; Yoshioka S; Tabata S; Yonetani N; Matsushita A; Imai Y; Ishikawa T
Leuk Lymphoma; 2016 Aug; 57(8):1945-8. PubMed ID: 26689650
[No Abstract] [Full Text] [Related]
28. First-line treatment of follicular lymphoma in the era of monoclonal antibodies.
Coiffier B
Clin Adv Hematol Oncol; 2005 Jun; 3(6):484-91, 505. PubMed ID: 16167027
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy after IFRT for follicular lymphoma.
Venkatesan P
Lancet Oncol; 2018 Aug; 19(8):e391. PubMed ID: 30017349
[No Abstract] [Full Text] [Related]
30. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
[TBL] [Abstract][Full Text] [Related]
31. Follicular lymphoma.
Ghielmini M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii151-3. PubMed ID: 20943608
[TBL] [Abstract][Full Text] [Related]
32. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
[TBL] [Abstract][Full Text] [Related]
33. Aggressive treatment in follicular non-Hodgkin's lymphoma.
Schouten HC
Br J Hosp Med; 1996 Nov 20-Dec 10; 56(10):525-8. PubMed ID: 8958406
[No Abstract] [Full Text] [Related]
34. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
35. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
[TBL] [Abstract][Full Text] [Related]
36. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.
Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E
Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641
[TBL] [Abstract][Full Text] [Related]
37. Open questions in watchful waiting for follicular lymphoma.
Sorigue M; Sancho JM; Ribera JM
Br J Haematol; 2017 Nov; 179(4):679-681. PubMed ID: 27390920
[No Abstract] [Full Text] [Related]
38. Follicular lymphoma: managing an indolent malignancy.
Hallam S; Montoto S
Br J Hosp Med (Lond); 2010 May; 71(5):258-62. PubMed ID: 20448493
[TBL] [Abstract][Full Text] [Related]
39. Ovarian Follicular Lymphoma Diagnosed Due to Hydronephrosis.
Noguchi S; Kimura Y; Shibano S; Ariake C; Iwasawa T; Oyama N; Sato H; Enomoto K; Takahashi N
Intern Med; 2023 Jan; 62(2):293-298. PubMed ID: 35732447
[TBL] [Abstract][Full Text] [Related]
40. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
McLaughlin P
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
